---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-032379"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:35:09.257903+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma raises $6.5M via public offering; FDA clears teen enrollment in Netherton Syndrome trials

## Summary
- Raised $6.5M gross from public offering of ADSs, pre-funded and Series D/E warrants at $1.60 combined per unit.
- Repriced 638,834 existing warrants from $13.20/$12.00 to $1.60 per ADS; extended expiration to March 7, 2029.
- FDA cleared recruitment of teen subjects (14+) into QRX003 trials for Netherton Syndrome, first non-adult inclusion under open IND.
- Teens on off-label systemic therapy eligible for open-label study; others eligible for placebo-controlled study.
- Net proceeds for general corporate purposes; offering closed March 7, 2024.

## SEC filing metadata
- accession: 0001104659-24-032379
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/0001104659-24-032379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/tm248307d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-032379
- JSON: https://secwatch.observer/filing/0001104659-24-032379.json
- Plain text: https://secwatch.observer/filing/0001104659-24-032379.txt

## Key facts
- Material Agreements
  Quoin Pharmaceuticals, Ltd. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee of 7.0% of the aggregate gross proceeds (effective 2024-03-04).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: cash fee of 7.0% of the aggregate gross proceeds
  - Effective: 2024-03-04
  source text: Pursuant to that certain placement agency agreement, dated March 4, 2024, by and between the Company and the Placement Agent (the "Placement Agency Agreement"), the Placement Agent was paid a cash fee of 7.0% of the aggregate gross proceeds to the Company from the sale of the ADSs, Pre Funded-Funded Warrants and Warrants in the Offering and the Company reimbursed the Placement Agent for (i) non-accountable expenses in an amount of 1.0% of the aggregate gross proceeds raised in the Offering and (ii) accountable expenses of the Placement Agent of $125,000 related to the legal fees.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/0001104659-24-032379-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.